Investing in a novel shorter treatment regimen for multidrug-resistant tuberculosis: to be repeated

Eur Respir J. 2017 Mar 22;49(3):1700081. doi: 10.1183/13993003.00081-2017. Print 2017 Mar.

Authors

Mohammed A Yassin¹, Ernesto Jaramillo², Eliud Wandwalo¹, Dennis Falzon³, Anna Scardigli¹, Osamu Kunii¹, Karin Weyer²

Affiliations

¹ Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland.
² Global TB Programme, World Health Organization (WHO/GTB), Geneva, Switzerland.
³ Global TB Programme, World Health Organization (WHO/GTB), Geneva, Switzerland [email protected].

PMID: 28331045
DOI: 10.1183/13993003.00081-2017

No abstract available

Publication types

Editorial

MeSH terms

Antitubercular Agents / administration & dosage*
Antitubercular Agents / economics
Biomedical Research / economics*
Drug Administration Schedule
Global Health
Humans
Tuberculosis, Multidrug-Resistant / drug therapy*
World Health Organization

Substances

Antitubercular Agents

Grants and funding

001/WHO_/World Health Organization/International